PLK1 and prostate cancer: Soon after, we have also assessed the therapeutic potential of those F3-SNALPs, upon encapsulation of a siRNA against PLK1 [153] in prostate cancer (PC3) and angiogenic endothelial (HMEC-1) cells, having observed a significant decrease in cell viability, which was mediated by a marked PLK1 silencing, both at the mRNA and protein levels.